Mepenzolate
Back to searchMolecule Structure
Scientific Name
Mepenzolate
Description of the Drug
Mepenzolate is a postganglionic parasympathetic inhibitor that was previously approved for improving the healing of gastric ulcers, but has been discontinued.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB04843
http://www.drugbank.ca/drugs/DB04843
Brand Name(s)
Not Available
Company Owner(s)
Sanofi Aventis Us Llc
Mechanism(s) Of Action
Target Name | Target Type | Action Type | Target ChEMBL ID |
---|---|---|---|
Muscarinic acetylcholine receptor M1 | SINGLE PROTEIN | ANTAGONIST | CHEMBL216 |
Muscarinic acetylcholine receptor M3 | SINGLE PROTEIN | ANTAGONIST | CHEMBL245 |
Clinical Trial(s)
Unichem Links
SureChEMBL | SCHEMBL2994933 | |
PharmGKB | PA164746250 | |
Human Metabolome Database | HMDB0015591 | |
DrugBank | DB04843 | |
PubChem | 4057 | |
LINCS | LSM-5102 | |
Nikkaji | J21.250D | |
BindingDB | 50377964 | |
EPA CompTox Dashboard | DTXSID2046969 | |
DrugCentral | 1689 | |
Guide to Pharmacology | 10470 | |
rxnorm | MEPENZOLATE BROMIDE | MEPENZOLATE |
ChEBI | 94411 |